Long, lustrous hair is a universal desire, but the journey to achieve it often leads people to the vitamin aisle. Shelves are ...

Inclusion criteria comprised patients over 18 years of age, diagnosed with moderate-to-severe psoriasis and treated with either guselkumab or risankizumab for a minimum of 52 weeks ... The ratios of ...

Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most participants with scalp psoriasis treated with icotrokinra achieved the study’s primary ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

It included 432 individuals over 12 years of age who had plaque psoriasis affecting up to 25% of the scalp and body, with a minimum scalp IGA score of 3 and body IGA score of 2. Average age was 47.3 ...

66% of patients with scalp psoriasis achieved a scalp-specific Investigator's Global Assessment (ss-IGA) c score of 0/1 compared to 11% receiving placebo (P<0.001) at 16 weeks.

Data presented at the 2025 Society for Investigative Dermatology (SID) Annual Meeting show 57% of patients treated with once daily icotrokinra achieved the study's primary endpoint with an ...

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...

It included 432 individuals over 12 years of age who had plaque psoriasis affecting up to 25% of the scalp and body, with a minimum scalp IGA score of 3 and body IGA score of 2. Average age was 47 ...

Scalp psoriasis often presents with persistent itch ... or 1 (almost clear) with a minimum two-grade reduction from baseline and a Body-Investigator Global Assessment score of 0 or 1 with the ...